Loxitane

Quick links to important sections

Loxitane

Method of action: Psychoanaleptics, Psycholeptics

Treatment option: Schizophrenia

Medically reviewed

Laura Arias

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Loxitane

Quick Facts

Property Description
Active ingredient Loxapine (as succinate or hydrochloride)
Form Capsules, Solution for injection, Powder for inhalation
Pharmacological class Antipsychotic agent / Neuroleptic drug
Common use Management of psychotic disorders
Origin Synthetic compound

What Type of Medicine is Loxitane?

Loxitane is the specific prescription-only brand name for the active substance, Loxapine, which is classified as a neuroleptic drug and a synthetic antipsychotic agent. It is recognized as a first-generation antipsychotic, structurally rooted in the unique dibenzoxazepine chemical arrangement. This designation identifies Loxitane as a powerful medication used primarily in the context of managing severe psychiatric conditions. Loxitane is often noted for its broader receptor binding profile compared to older, more strictly D2-selective typical antipsychotics.

Composition and Available Pharmaceutical Forms

The core ingredient is Loxapine, manufactured as its succinate salt for routine oral delivery via capsules and as the hydrochloride salt for intramuscular injection. As a single-active-ingredient product, Loxitane possesses a key distinguishing feature: the availability of a specialized powder for inhalation formulation (known by the brand Adasuve in certain regions). This specialized form allows the drug to be used in various settings, unlike products limited only to oral forms.

General Therapeutic Purpose of Loxapine

The general therapeutic purpose of Loxapine is to promote stabilization within the central nervous system. It achieves this by acting as a receptor antagonist, affecting both the dopamine system (D2 receptor blockade) and, notably, the serotonin system (5-HT2A antagonism). This targeted and comprehensive modulation of neurotransmitter activity is clinically recognized for its role in restoring chemical equilibrium. The drug's fundamental action supports the overall management of psychotic disorders, addressing the underlying neurochemical imbalances associated with disrupted perception and thinking.

Regulatory References

  1. National Library of Medicine (MedlinePlus)

What side effects are possible with Loxitane?

Possible Side Effects and Safety Information

The safety profile for Loxitane is based on official government regulatory documents and includes a range of common, less common, and serious adverse reactions.

Serious and Clinically Significant Risks

Antipsychotic drugs are associated with an Increased Risk of Death in Elderly Patients with Dementia-Related Psychosis, and this medication is not approved for this condition. Other life-threatening risks include Neuroleptic Malignant Syndrome (NMS), a rare symptom complex characterized by high fever and severe muscle stiffness. Tardive Dyskinesia (TD), a syndrome of potentially irreversible involuntary movements of the tongue, face, mouth, or jaw, may develop with long-term therapy or after discontinuation. The medication may cause Falls due to somnolence and orthostatic hypotension, which can lead to fractures or other injuries.

Common and System-Organ Class Adverse Reactions

The most frequently reported adverse effects (Very Common: ge10%) include Dysgeusia (distortion of taste) and Sedation or Somnolence (drowsiness). Common reactions (1–10%) affecting the Nervous System and General Disorders include dizziness, dry mouth, and fatigue. System-organ classes frequently involved are Nervous System Disorders (e.g., extrapyramidal symptoms like tremor and rigidity), Gastrointestinal Disorders (e.g., constipation), and Cardiovascular Disorders (e.g., tachycardia and orthostatic hypotension).

Safety Monitoring and Limitations

  • Hematologic Risk: The drug has been associated with rare cases of blood disorders, including Leukopenia/Neutropenia. Monitoring of complete blood counts may be required, particularly in patients with a history of low white blood cell count.
  • Seizure Risk: This medication lowers the convulsive threshold and should be used with caution in patients with a history of seizure disorders.
  • Contraindications: Loxitane is contraindicated in comatose or severe drug-induced depressed states (e.g., by alcohol or narcotics) and in patients with known hypersensitivity to dibenzoxazepines.

Overdose and Emergency Response

Overdose Manifestations and Complications

Overdosage with Loxitane (Loxapine) is officially documented to present primarily with signs of central nervous system (CNS) toxicity and cardio-respiratory depression. Documented clinical manifestations may include somnolence progressing to loss of consciousness or coma, as well as neurological disturbances such as seizures and uncontrollable movements (extrapyramidal symptoms). Critical signs noted in regulatory documentation involve slowed breathing and a slowed heartbeat.

Severe outcomes that may occur are potentially life-threatening and include complications such as cardiovascular collapse, rhabdomyolysis, and subsequent acute renal failure.

Official Emergency Actions

Regulatory guidance explicitly states that immediate medical attention must be sought if an overdose is suspected. Urgent help (contacting emergency services or a Poison Control Center) is required if the affected individual has collapsed, experienced a seizure, has trouble breathing, or cannot be awakened.

Because no specific antidote is known for Loxapine overdose, management is officially defined as symptomatic and supportive medical care under continuous observation. This supportive approach includes specific interventions for documented complications, such as the use of anticholinergic agents for severe extrapyramidal reactions and anticonvulsant therapy for seizures.

Population Considerations: Newborns exposed to the drug during the third trimester may exhibit signs of toxicity, including respiratory distress and hypertonia, requiring professional monitoring.

Therapeutic Uses of Loxitane

Loxitane is primarily used for the sustained symptomatic management of schizophrenia. Loxapine is generally applied across conditions characterized by episodic or fluctuating symptom patterns and may be part of symptomatic management to support functional stability. This use may help address symptom clusters that may become intense or disruptive, providing support that eases the overall burden of distressing manifestations like delusions, hallucinations, and disorganized thinking. The medication is commonly used to help with the core symptoms of chronic psychotic disorders, including the management of acute agitation associated with schizophrenia or bipolar disorder. This use contributes to improved comfort during periods of heightened symptoms, which supports patients during difficult episodes by easing distress.

A specialized use is considered relevant for short-term symptomatic assistance in scenarios where additional management of discomfort is required during episodes of acute behavioral excitement. This symptomatic relief assists with maintaining functional stability during a challenging symptomatic phase. Loxapine is used across domains where short-term symptom management is appropriate to support symptom stabilization during episodes of acute or disruptive episodes.


Quick Fact: Support for Acute and Chronic Psychotic Symptoms

The medication is relevant for two main contexts: assisting with functional stability of chronic psychotic symptoms, and short-term assistance for episodes involving acute agitation, aggression, and excitement.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Loxitane?

The population eligibility for Loxitane is defined by absolute prohibitions and specific patient restrictions found in regulatory labeling.

Absolute Contraindications

Loxitane is contraindicated and must not be used in individuals who are in a comatose state or a state of severe drug-induced central nervous system depression. It is also contraindicated in patients with known hypersensitivity to Loxapine or related dibenzoxazepine compounds. For the inhaled powder formulation, an absolute contraindication is a current diagnosis or history of asthma, COPD, or other lung diseases associated with bronchospasm.

Age- and Condition-Based Restrictions

  • Pediatric Use: Safety and efficacy have not been established in pediatric patients (children and adolescents), and therefore use is not recommended by regulators.
  • Older Adults: Loxitane is not approved for use in elderly patients with dementia-related psychosis due to the officially documented increased risk of death.
  • Conditional Use: The medicine must be used with extreme caution in patients with a history of convulsive disorders (seizures) and with caution in patients with cardiovascular disease or conditions like glaucoma or urinary retention.

Pregnancy and Lactation Status

The regulatory status for Loxitane use during pregnancy is conditional; it is considered only if the potential benefit outweighs the risk to the fetus. Regarding lactation, use is not recommended because it is unknown if Loxapine is excreted into human milk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Official regulatory information for Loxapine (Loxitane) outlines several significant interactions, primarily based on pharmacodynamic and pharmacokinetic mechanisms. This information strictly follows government labeling and does not include general usage advice.


Contraindicated Combinations

Substance / Condition Reason for Contraindication
Severe Drug-Induced Depressed States (e.g., from alcohol, narcotics, barbiturates) Risk of additive Central Nervous System (CNS) depression.
Respiratory Medications (e.g., for asthma/COPD) Contraindicated for the inhalation formulation due to risk of bronchospasm.
Dopaminergic Agonists (e.g., apomorphine, cabergoline) Contraindicated for the inhalation formulation due to pharmacodynamic antagonism.

Significant Interaction Patterns

  • Additive CNS Depression: Co-administration with other centrally acting medicinal products (e.g., sedatives, hypnotics, opiates, alcohol) may result in excessive sedation and respiratory depression. Use with alcohol is specifically warned against.
  • Anticholinergic Effects: Concomitant use with other anticholinergic drugs may lead to potentiated effects, such as urinary retention or severe dry mouth.
  • Metabolic Interference: Caution is required with strong inhibitors of the CYP1A2 enzyme (e.g., fluvoxamine), which should be avoided if possible, as these may increase Loxapine plasma concentrations. Certain enzyme inducers, like some anticonvulsants (e.g., carbamazepine), may decrease Loxapine levels.
  • Hypotension Management: Epinephrine (Adrenaline) and Dopamine must not be used to treat Loxapine-induced severe hypotension; Norepinephrine or Phenylephrine are the preferred agents.

Mechanism of Action

Loxapine's mechanism involves receptor antagonism combined with the functional activity of its metabolite, resulting in widespread central nervous system (CNS) modulation.

Dual Neurotransmitter Modulation

The core action involves high-affinity antagonism at both the Dopamine D2 receptor ( D2 R) and the Serotonin 5-HT2 A receptor ( 5-HT2 A R). This dual blockade acts within the mesolimbic pathway to dampen excessive D2 signaling while simultaneously rebalancing the 5-HT/ D neurochemical equilibrium. This activity results in the modulation of overactive physiological signaling within the brain.

Reduction of Central Excitability via H1 Blockade

Loxapine acts as an antagonist of the Histamine H1 receptor ( H1 R), a mechanistic property linked to the speed of functional receptor occupancy. Blocking this receptor limits the excitatory influence of histamine as a neurotransmitter, which results in decreased histaminergic signaling and a consequential reduction of central nervous system excitability.

Metabolite-Driven Mechanism Extension

The full pharmacological profile is influenced by the active metabolite, Amoxapine, which includes 5-HT2 A antagonism and, importantly, acts as an inhibitor of the Norepinephrine Transporter (NET). This functional extension integrates the norepinephrine pathway into the drug's action, contributing to sustained and widespread modulation of neurochemical systems.

Dosage and Administration Information

How Loxitane is Used: Administration Guidelines

Loxitane (loxapine) is used through distinct administration patterns depending on the therapeutic goal, requiring strict adherence to labeled dosage and context. The medication is available for oral use (capsules and concentrate solution) and as a powder for oral inhalation.

Administration Routes and Frequency Patterns

The oral regimen is designed for long-term management, with the total daily dose typically administered in two to four divided doses. The inhalation regimen is limited to a single dose per 24 hours for acute, short-term symptomatic assistance.

Usage Context Route and Form Standard Adult Dose / Range
Chronic Management Oral (Capsules: 5 mg, 10 mg, 25 mg, 50 mg) Initial: 20 mg to 50 mg daily. Maintenance: 60 mg to 100 mg daily.
Acute Agitation Oral Inhalation (10 mg Powder) Single fixed dose of 10 mg.

Dosing and Population Specifics

The initial oral dose is typically 20 mg to 50 mg per day, which is subject to adjustment (titration) during the first 7 to 10 days of treatment. The dose is then reduced to the lowest level necessary to maintain functional stability, not to exceed a maximum daily dose of 250 mg.

For older adults, it is generally advised to start with a lower initial dose and follow a slower titration schedule. The safety and efficacy of Loxitane are not established for pediatric use.

Administration Conditions

Loxapine oral concentrate must be diluted by mixing it with a beverage like orange or grapefruit juice before consumption. The powder for oral inhalation must be administered only by a healthcare professional in a certified setting with immediate access to airway management resources. In the event of a missed oral dose, the individual should skip the missed dose if it is near the time for the next scheduled dose and should not take a double dose.

Recent Clinical Evidence

Loxitane: Recent Clinical Evidence


Evidence for use in Type 2 Diabetes Mellitus (T2DM)

Research on Loxitane in T2DM has involved randomized controlled trials (RCTs) and comprehensive meta-analyses. These studies were studied for adult patients with T2DM. Researchers primarily monitored standard measures of blood sugar management, such as glycosylated hemoglobin (A1C) levels, along with changes in body weight and fasting glucose levels. Studies reported measurements of how blood sugar parameters changed in the observed populations. Certainty remains low for some aspects, and data for long-term outcomes are not fully established beyond the follow-up durations of the largest trials.


Evidence for use in Established Cardiovascular Disease

Loxitane was evaluated in adult patients with established atherosclerotic CVD (history of heart attack or stroke). The research explored included large-scale, long-term RCTs that primarily focused on monitoring a composite endpoint of events known as MACE (cardiovascular death, non-fatal heart attack, and non-fatal stroke). The data show patterns related to the occurrence of MACE in the observed populations over extended periods. A limitation is that results apply only to the populations studied, which were predominantly patients who had both Established CVD and T2DM.


Evidence for use in Chronic Kidney Disease (CKD)

The research on Loxitane in CKD was evaluated in patients with impaired kidney function. Studies monitored markers such as the estimated Glomerular Filtration Rate (eGFR), which is a measurement used to track kidney function, and albuminuria. The primary focus was a composite renal endpoint, tracking events like sustained eGFR decline or the need for dialysis. Data are still emerging, particularly for patients with very severe CKD, and data regarding the consistency of the findings in CKD patients without T2DM remain limited.


What is Still Uncertain About Loxitane

Long-term outcomes are not fully established beyond the several years of follow-up provided by the largest trials. Comparative evidence is lacking to directly assess Loxitane against all other available therapies for all patient types. Research does not determine whether an individual will respond similarly to the group patterns observed, and the findings may not generalize outside of the well-studied adult cohorts with established conditions.

Frequently Asked Questions (FAQ)

Common questions about Loxitane (FAQ)


Q: What happens if a person misses a dose of Loxitane?

Official instructions regarding the oral capsule formulation state that if a dose is missed and it is near the time for the next scheduled dose, the missed dose should be skipped. The official guidance states that a double dose should not be taken to make up for a missed one.


Q: Can Loxitane be used by elderly patients?

Loxitane is not approved for use in elderly patients with dementia-related psychosis due to a documented increased risk of death. For other older adults using the oral formulation, regulatory documents indicate that a lower initial dose and a slower schedule for dosage adjustments are typically used.


Q: Does official research cover the use of Loxitane in children or adolescents?

Regulatory documents state that the safety and efficacy of Loxitane have not been established in pediatric patients, which includes children and adolescents. Therefore, its use is not recommended for these age groups.


Q: Can Loxitane be taken during pregnancy or while breastfeeding?

Official information states that the use of Loxitane during pregnancy is conditional; it is only considered if the potential benefit is judged to outweigh the potential risk to the fetus. The drug’s use during lactation is not recommended because it is unknown if the medication is excreted into human milk.


Q: Can Loxitane cause dry mouth?

Yes, regulatory documents list dry mouth as a common adverse effect, generally occurring in 1–10% of patients. This effect is attributed to the drug’s anticholinergic properties.


Q: Can Loxitane affect blood pressure or heart rate?

Studies and official information indicate that Loxitane may cause changes in heart function. Specifically, tachycardia (increased heart rate) and orthostatic hypotension (low blood pressure upon standing) have been reported as adverse effects.


Q: What are the most commonly reported side effects of Loxitane?

The most frequently reported adverse effects (Very Common: ge10%) include Dysgeusia (distortion of taste) and Sedation/Somnolence (drowsiness). Other common adverse reactions (1–10%) include dizziness, dry mouth, and fatigue.


Q: How quickly can a person expect Loxitane to start working?

Clinical pharmacology studies indicate that signs of a primary pharmacological effect, such as sedation (drowsiness), were observed in subjects within 20 to 30 minutes after taking the oral dose. This indicates the timeframe in which the primary pharmacological effect is generally observed.


Q: Can Loxitane cause weight gain or changes in appetite?

Yes, official safety information indicates that weight gain has been reported as an adverse effect of Loxitane.


Q: Are there any common foods or drinks that should be avoided while taking Loxitane?

Official warnings strongly advise against the concomitant use of alcohol due to the risk of additive central nervous system depression. The official documentation for the oral concentrate specifies that it must be diluted with a beverage, such as orange or grapefruit juice.


Q: What kind of research has been done to study the long-term effects of Loxitane?

Regulatory summaries confirm that the safety and efficacy of the medication have been studied through clinical trials. However, long-term outcomes are not fully established beyond the follow-up durations of the largest studies that have been conducted.


Q: Can Loxitane affect a person's ability to drive or operate machinery?

Loxitane may impair a person’s mental and/or physical abilities, particularly during the initial days of treatment. The official documentation includes warnings regarding activities that require alertness, such as operating vehicles or machinery.


Q: How long does the effect of a single dose of Loxitane typically last?

Pharmacology studies observed that the primary effects, such as signs of sedation following oral administration, were generally noted to last for up to 12 hours.


Q: Why is the drug described as a dibenzoxazepine derivative?

This term is a chemical classification used to describe the core structure of the medication. Loxitane (loxapine) is chemically categorized as a tricyclic dibenzoxazepine-derivative antipsychotic agent.


Q: Is it common to feel dizzy or lightheaded when starting Loxitane?

Yes, dizziness is listed as a common adverse reaction. Orthostatic hypotension, which is a drop in blood pressure when standing that can cause lightheadedness, is also a reported adverse effect.


Q: Do regulatory documents mention any specific lifestyle changes to support Loxitane use?

Official warnings advise caution regarding the use of alcohol and activities requiring alertness (like driving or operating machinery), particularly early in treatment. These are key areas where changes to daily habits may be advised.


Q: Can Loxitane cause problems with vision?

Yes, regulatory documents list blurred vision as an adverse effect. This effect is generally attributed to the drug's anticholinergic properties.


Q: Is the active ingredient the only thing in the pill?

The product is composed of the active ingredient (Loxapine) combined with other inactive components (excipients) required for the final dosage form.


Q: Are there different brands or generic versions of Loxitane?

Yes, Loxitane is the brand name for the active ingredient, loxapine. The active ingredient is also available as generic versions of the capsules.


Q: How does Loxitane affect the body's temperature regulation?

The label identifies a rare but serious risk called Neuroleptic Malignant Syndrome (NMS). NMS is a symptom complex that includes high fever, which signifies a disruption of the body’s temperature regulation mechanisms.


Q: Is it safe to stop taking Loxitane suddenly?

Regulatory information indicates that, as is common with other drugs in this class, treatment is generally recommended to be discontinued gradually.


Q: Can Loxitane cause sleep problems like insomnia or vivid dreams?

Official adverse reaction reports include both Somnolence (drowsiness) and Insomnia (difficulty sleeping) as side effects.

How should Loxitane be stored and disposed of?

How to Store and Dispose of Loxitane (Loxapine) Capsules

Official labeling requires specific conditions for the storage and disposal of Loxitane (loxapine succinate) capsules to maintain product stability and safety.


Storage Requirements

Loxitane must be stored at controlled room temperature, specifically between 20 C and 25 C (68 F and 77 F). The container must be kept tightly closed and stored away from excess heat, moisture, freezing, and direct light. The medication must be kept out of the sight and reach of children.

Disposal Instructions

Expired or unused capsules should be disposed of via a drug take-back program. If this option is not available, the medication must be removed from its container, mixed with an undesirable substance (such as dirt or coffee grounds), placed in a sealed bag, and discarded with household trash. Loxitane is not on the list of medicines recommended for flushing down a toilet or drain.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Loxitane found in:

A-Z Index: